BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 20, 2005
 |  BioCentury  |  Strategy

Stepwise into cancer

Cephalon Inc. has had a toehold in the cancer space since its 2000 acquisition of Anesta Corp. gave it Actiq oral transmucosal fentanyl, which is marketed for breakthrough cancer pain. The company also has two cancer compounds in the clinic. But with two recent deals, the company has firmly laid the foundation stones of what it believes will be a substantial presence in the onco-logy market. The first foray focuses on blood-related cancers, but the company has ambitions to build a position in treating solid cancers.

The latest move...

Read the full 446 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >